Anaptysbio Inc (NASDAQ:ANAB) Sellers Increased Their Shorts By 3.2%

May 16, 2018 - By Robert Reynolds

Anaptysbio Inc (NASDAQ:ANAB) had an increase of its shorted shares by 3.2%. It was announced in May by FINRA the 2.60 million shorted shares on ANAB. The up change of 3.2% from 2.52 million shares was reported. Anaptysbio Inc (NASDAQ:ANAB) has 264,700 shares average volume. It’ll cost 10 days for ANAB to recover its previous position. Anaptysbio Inc float short is 21.69%.

ANAB is touching $88.71 during the last trading session, after decreased 0.68%.Currently AnaptysBio, Inc. is uptrending after 290.56% change in last May 16, 2017. ANAB has also 101,764 shares volume. ANAB outperformed the S&P500 by 279.01%.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation.The firm is worth $2.08 billion. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.Currently it has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

A couple more AnaptysBio, Inc. (NASDAQ:ANAB) news were published by: Streetinsider.com which released on May 09, 2018 “AnaptysBio (ANAB) PT Lowered to $150 at SunTrust Robinson Humphrey”, also Globenewswire.com on April 27, 2018 published “AnaptysBio To Participate in Upcoming Investor Conferences”, the next Nasdaq.com is “AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress” on May 01, 2018. Streetinsider.com has article titled “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in …”.

AnaptysBio, Inc. (NASDAQ:ANAB) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: